Legislation Reproductive Rights Roe v. Wade Abortion Bans State Laws Supreme Court Abortion Rights Abortion Laws Public Opinion Pro-Life Movement Republican Party Abortion Ban Abortion Access Abortion Restrictions State Legislation Federal Abortion Ban State Bans Anti-Abortion Movement Access Abortion Legislation Texas Anti-Abortion Groups Republican Candidates Mifepristone National Ban Women's Rights Laws Federal Ban Democratic Party National Abortion Ban Florida State Abortion Laws Texas Supreme Court State Abortion Bans Pro-life Movement Bans Medication Abortion Pro-life Legal Issues Trump's stance on abortion Ballot Measures Six-Week Abortion Ban Legalization Lawsuit Arizona Abortion Pill Constitutional Amendments Late-term Abortion Anti-Abortion Laws Ohio Late-Term Abortion Roe v Wade Donald Trump State Restrictions Legal Challenges Elections Republican Stance Pro-Life Federal Law FDA Abortion Policies Abortion Policy Democrats Reproductive Health Care Trump's Position FDA Approval March for Life Exceptions Supreme Court Ruling Pro-Choice Movement Kentucky Fetal Personhood Anti-Abortion Activism Abortion Debate Trump Criminalization Political Parties Republican Views Trump's Stance Anti-Abortion Candidates Republicans State-Level Bans State Referendums Ron DeSantis Lawsuits Pro-Life Advocacy Pro-Choice Missouri State Constitutional Amendments State Policies State Abortion Restrictions Supreme Court Rulings Texas Abortion Ban State vs Federal Regulation Debate Anti-Abortion Legislation Idaho Federal Legislation Late-term abortion Abortion Politics
Speakers at a Capitol press conference said the FDA’s promised mifepristone safety review has stalled.
